國立虎尾科技大學 |

Optimization of Pharmaceutical R&D Programs and Portfolios = Design and Investment Strategy /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Optimization of Pharmaceutical R&D Programs and Portfolios/ edited by Zoran Antonijevic.
其他題名:	Design and Investment Strategy /
其他作者:	Antonijevic, Zoran.
面頁冊數:	VIII, 202 p. 38 illus., 24 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Operations research. -
電子資源:	https://doi.org/10.1007/978-3-319-09075-7
ISBN:	9783319090757

Optimization of Pharmaceutical R&D Programs and Portfolios = Design and Investment Strategy /
Optimization of Pharmaceutical R&D Programs and PortfoliosDesign and Investment Strategy /[electronic resource] :edited by Zoran Antonijevic. - 1st ed. 2015. - VIII, 202 p. 38 illus., 24 illus. in color.online resource.

Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development -- Clinical Aspects of Pharmaceutical Portfolio Management -- Drug Development and the Cost of Capital -- Investment Considerations for Pharmaceutical Product Portfolios -- Challenges of Portfolio Management in Pharmaceutical Development -- Impact of Phase 2b Strategies on Optimization of Drug Development Programs -- Using Decision Analysis to Support the Design of Clinical Trials at a Program Level -- Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications -- Maximizing Return on Investment in Phase II Proof-of-Concept Trials -- Portfolio Optimization of Therapies and Their Predictive Biomarkers -- Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline.

Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of the published literature comes from the commercial perspective, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on the impact of study design on PoS, and ultimately a portfolio’s value. Design options that are discussed are dose-selection strategies, adaptive design, and enrichment. Some development strategies that are examined are indication sequencing, optimal number of programs, and optimal decision criteria. This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial, and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial, and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists, and clinicians. Early chapters describe approaches to portfolio optimization from big pharma, and venture capital standpoints, focusing on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a basic knowledge of statistics by a reader. .

ISBN: 9783319090757

Standard No.: 10.1007/978-3-319-09075-7doiSubjects--Topical Terms:

573517
Operations research.

LC Class. No.: HD30.23

Dewey Class. No.: 658.40301

Optimization of Pharmaceutical R&D Programs and Portfolios = Design and Investment Strategy /
LDR:03934nam a22004095i 4500 001 962233
003 DE-He213
005 20200918224745.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319090757 $9 978-3-319-09075-7
024 7 $a 10.1007/978-3-319-09075-7 $2 doi
035 $a 978-3-319-09075-7
050 4 $a HD30.23
072 7 $a KJT $2 bicssc
072 7 $a BUS049000 $2 bisacsh
072 7 $a KJT $2 thema
072 7 $a KJMD $2 thema
082 0 4 $a 658.40301 $2 23
245 1 0 $a Optimization of Pharmaceutical R&D Programs and Portfolios $h [electronic resource] : $b Design and Investment Strategy / $c edited by Zoran Antonijevic.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a VIII, 202 p. 38 illus., 24 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development -- Clinical Aspects of Pharmaceutical Portfolio Management -- Drug Development and the Cost of Capital -- Investment Considerations for Pharmaceutical Product Portfolios -- Challenges of Portfolio Management in Pharmaceutical Development -- Impact of Phase 2b Strategies on Optimization of Drug Development Programs -- Using Decision Analysis to Support the Design of Clinical Trials at a Program Level -- Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications -- Maximizing Return on Investment in Phase II Proof-of-Concept Trials -- Portfolio Optimization of Therapies and Their Predictive Biomarkers -- Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline.
520 $a Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of the published literature comes from the commercial perspective, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on the impact of study design on PoS, and ultimately a portfolio’s value. Design options that are discussed are dose-selection strategies, adaptive design, and enrichment. Some development strategies that are examined are indication sequencing, optimal number of programs, and optimal decision criteria. This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial, and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial, and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists, and clinicians. Early chapters describe approaches to portfolio optimization from big pharma, and venture capital standpoints, focusing on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a basic knowledge of statistics by a reader. .
650 0 $a Operations research. $3 573517
650 0 $a Decision making. $3 528319
650 0 $a Mathematical optimization. $3 527675
650 0 $a Statistics . $3 1253516
650 1 4 $a Operations Research/Decision Theory. $3 669176
650 2 4 $a Optimization. $3 669174
650 2 4 $a Statistics for Life Sciences, Medicine, Health Sciences. $3 670172
700 1 $a Antonijevic, Zoran. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1063111
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319090740
776 0 8 $i Printed edition: $z 9783319090764
776 0 8 $i Printed edition: $z 9783319343129
856 4 0 $u https://doi.org/10.1007/978-3-319-09075-7
912 $a ZDB-2-SBE
912 $a ZDB-2-SXBM
950 $a Business and Economics (SpringerNature-11643)
950 $a Business and Management (R0) (SpringerNature-43719)